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ABSTRACT 
 
 Cartilage defects, whether caused by osteoarthritis, joint trauma, or other 
disease, have provoked a wide variety of tissue engineering scaffold strategies in 
recent years. Traditionally, cartilage tissue engineering scaffolds have utilized 
synthetic polymer components to form hydrogels or other porous matrices. However, 
components found within the extracellular matrix (ECM) such as collagen, 
glycosaminoglycans (GAGs), and ECM-based matrices have emerged as an essential 
subset of biomaterials for tissue engineering scaffolds. The objective of this research 
was to develop and evaluate decellularized cartilage (DCC) as a chondroinductive 
material for cartilage tissue engineering applications. This work was successful in 
developing a decellularization method for hyaline cartilage fragments that removed 
99% of cells, while retaining 87% of GAGs and also in determining a method to 
produce a homogenous nanopowder of DCC. Additionally, this research was the first 
to examine the ability of DCC to induce chondrogenesis in stem cells by quantifying 
gene expression of chondrogenic markers. The results demonstrate for the first time 
that DCC can indeed upregulate chondrogenic markers and may be a new 
chondroinductive material that can provide microenvironmental cues and signaling to 
promote stem cell differentiation in cartilage regeneration. 
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CHAPTER 1: Introduction 
The overall objective of this thesis was to determine the feasibility and 
potential of decellularized hyaline cartilage tissue as a chondroinductive material for 
cartilage tissue engineering applications.  To achieve this objective, three phases were 
recognized: the decellularization phase, material characterization phase, and cellular 
response phase.  In the decellularization phase, the objective was to identify 
conditions and tissue preparation methods in order to obtain cartilage extracellular 
matrix with greater than 97% cellular removal, while obtaining glycosaminoglycan 
content concentrations similar to native cartilage tissue. In the material 
characterization phase, the objective was to further elucidate properties of the 
acellular cartilage ECM, including methods for grinding the tissue into a fine powder, 
characterizing particle size, and chemical composition. In the cellular response phase, 
decellularized cartilage powder was evaluated in two different in vitro cell culture 
environments – pellet culture and encapsulated within an agarose hydrogel. Pellet 
culture was used to quantify gene expression in response to the decellularized 
cartilage powder and encapsulation within a hydrogel was used to quantify DNA 
content in gels over a 3-week culture period.  
To achieve the overall objective, two specific aims were designed: (1) to 
decellularize and characterize hyaline cartilage, and (2) to evaluate cellular response to 
decellularized cartilage powder. 
The organization of the remaining chapters is as follows: 
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 Chapter 2 serves to provide a complete review of the literature in the area of 
using raw materials as components of tissue engineering scaffolds, which is pertinent 
to subsequent chapters. Also provided in Chapter 2 is the background literature on the 
limited use of decellularized cartilage in regenerative medicine solutions to lead into 
the study presented in Chapter 3.  
 Following the establishment of pertinent background information, Chapter 3 
serves to satisfy the aforementioned Specific Aims. The deliverables include 
biochemical analyses of decellularized cartilage, chemical composition analysis by 
Fourier transform infrared spectroscopy, particle size analysis by transmission electron 
microscopy, and cellular response characterized by gene expression and cell 
proliferation. 
 Chapter 4 presents the conclusion where findings from all experiments are 
summarized. Possible future research directions are also presented. 
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CHAPTER 2: Leveraging ‘‘Raw Materials’’ as Building Blocks and 
Bioactive Signals in Regenerative Medicine1 
 
CHAPTER PURPOSE:   
 This chapter serves as a review of the recent literature surrounding the use of 
raw materials in tissue engineering scaffolds. For this article, a raw material was 
defined as a material that is found naturally within the body. 
2.1 ABSTRACT!
Components found within the extracellular matrix (ECM) have emerged as an 
essential subset of biomaterials for tissue engineering scaffolds. Collagen, 
glycosaminoglycans (GAGs), bioceramics, and ECM-based matrices are the main 
categories of “raw materials” used in a wide variety of tissue engineering strategies. 
The advantages of raw materials includes their inherent ability to create a 
microenvironment that contains physical, chemical, and mechanical cues similar to 
native tissue, which prove unmatched by synthetic biomaterials alone. Moreover, 
these raw materials provide a head start in the regeneration of tissues by providing 
building blocks to be bioresorbed and incorporated into the tissue as opposed to 
being biodegraded into waste products and removed. This article reviews the 
strategies and applications of employing raw materials as components of tissue 
engineering constructs. Utilizing raw materials holds the potential to provide both a 
scaffold and a signal, perhaps even without the addition of exogenous growth factors 
! ! ! ! !
1 Published as Amanda N. Renth and Michael S. Detamore, “Leveraging “raw materials” as building 
blocks and bioactive signals in regenerative medicine,” Tissue Engineering Part B, 18(5): 341-362, 2012. 
This is a copy of the article published in Tissue Engineering Part B © 2012 copyright Mary Ann Liebert, 
Inc.; Tissue Engineering Part B is available online at: http://online.liebertpub.com. 
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or cytokines. Raw materials contain endogenous proteins that may also help to 
improve the translational success of tissue engineering solutions to progress from 
laboratory bench to clinical therapies. Traditionally, the tissue engineering triad has 
included cells, signals, and materials. Whether raw materials represent their own new 
paradigm or are categorized as a bridge between signals and materials, it is clear that 
they have emerged as a leading strategy in regenerative medicine. The common use 
of raw materials in commercial products as well as their growing presence in the 
research community speak to their potential. However, there has heretofore not been 
a coordinated or organized effort to classify these approaches, and as such we 
recommend that the use of raw materials be introduced into the collective 
consciousness of our field as a recognized classification of regenerative medicine 
strategies. 
 
2.2 INTRODUCTION 
As the intertwined fields of tissue engineering and regenerative medicine 
continue to grow and evolve, the search for a “perfect” scaffold inevitably continues. 
This ongoing quest to search for new materials and fabrication techniques has led 
researchers anywhere from insect cuticle1, 2 to precious metals and minerals3 over the 
past decade. Researchers are continuously finding new materials and technology for 
fabricating scaffolds with heightened mechanical integrity, porosity, biocompatibility, 
and biodegradability. Hollister4 described biomaterials used in tissue engineering 
scaffolds as the distinct “lynch pin” for finding effective regenerative solutions. Most 
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attribute the lack of efficacy of biomaterials to the inability of materials to mimic the 
extracellular matrix (ECM) when compared to natural tissues and organs of the body.5 
Recent trends in the field suggest that it may be appropriate to ask the question, 
“Have we looked too far for the ideal, synthetic biomaterial and missed the actual 
building blocks needed for scaffolds in this process?” Utilization of materials that occur 
naturally within the human body such as collagen, chondroitin sulfate, and calcium 
phosphates have gained immense attention within the tissue engineering community. 
This review seeks to indicate the emergence of raw materials as components of 
tissue engineering scaffolds. For the purpose of this review, we define raw materials as 
those found naturally within the human body, such as collagen, glycosaminoglycans 
(GAGs), bioceramics, and ECM-based matrices. Several comprehensive reviews of non-
mammalian, natural polysaccharides such as alginate, chitosan, dextran and gelatin 
have been detailed extensively in the literature.5-9 In this review, we intend to instead 
highlight the most widely used mammalian raw materials and the strategies behind 
using these materials as building blocks for tissue engineering scaffolds. In addition, 
we seek to review the connection made to formulate scaffolds based upon 
components of native extracellular matrix, which has been used as a strategy by many 
in the field, but has not been collectively been brought to the attention of our field as 
a classification of strategies, but which perhaps should become part of our collective 
consciousness. 
Traditionally, the most common strategy to develop a tissue-engineered 
construct is through a combination of the factors described in the tissue engineering 
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triad (Fig. 1): scaffolds, signals, and cells. Scaffold development has attracted immense 
attention among researchers to design biomaterials with highly specific properties. 
The primary objective of a tissue engineering scaffold is to emulate the natural 
environmental conditions of the target tissue, while contributing to the synthesis of 
new tissue.8, 10 Sokolsky-Papkov et al.11 outlined the ideal criteria for tissue engineering 
constructs: (a) sufficient mechanical properties, (b) low toxicity, (c) mimic the native 
extracellular matrix, (d) support cell adhesion and migration, and (e) degradation rate 
that is approximately equal to the growth rate of new tissue. Selection of the 
appropriate biomaterial(s) to construct a scaffold must take into consideration the 
differences that exist between the components, types, and organization of both the 
cells and the surrounding extracellular matrix of the tissue.12 One of the main 
Cells 
Scaolds 
Signals 
RAW MATERIALS 
Figure 1. Schematic of the traditional tissue engineering triad 
illustrating the potential of raw materials to bridge the gap 
between scaolds and signals. 
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advantages of raw materials is the ability of the body to recognize and metabolize 
these scaffold components in the local microenvironment, which mitigates toxicity or 
chronic inflammatory response that may be observed with synthetic polymers.13 
Ultimately, the scaffold materials will influence multiple interactions in the 
microenvironment surrounding an implanted scaffold, which is crucial to the success 
or failure of tissue regeneration. Investigations of biomaterial-based “physical” signals 
propose that cell-biomaterial components and orientation at the micro/nanoscale 
level may affect cell survival, differentiation, and motility through interactions 
between cell receptors and ECM molecules.12, 14 Toh et al.15 as well as Marklein and 
Burdick16 have suggested the importance of optimizing scaffold materials and 
fabrication processes to modulate these interactions. The researchers noted that 
physical cues, such as the scaffold formulation and/or geometry, and mechanical cues, 
such as matrix elasticity, should be controlled to aid in the proliferation and 
differentiation of stem cells.15, 16 In addition, inherent adhesive cues or peptides and 
immobilized cues can also be incorporated into the biomaterial to manipulate the cell-
matrix interface.15, 16 Adopting a methodology that focuses on cell-scaffold interactions 
provides an effective strategy for utilizing material selection and fabrication to bridge 
two components of the tissue engineering triad – scaffolds and signals (Fig. 1). For 
example, selecting a collagen microparticle scaffold could affect three of these cues 
through high surface area and porosity (scaffold and geometric cue),14 soft matrix 
rigidity (mechanical cue), and inherent adhesive RGD (Arg-Gly-Asp) sequences.17 All of 
these scaffold attributes can collectively influence the local scaffold microenvironment 
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before the addition of growth factors or cytokines, which is a common theme in many 
tissue engineering strategies.18 Raw materials such as collagen can effectively deliver 
microenvironmental cues without additional materials or fabrication steps that may 
be needed in a synthetic polymer scaffold. Therefore, the selection of raw materials as 
scaffold components could potentially bridge the gap between scaffolds and signals 
in the traditional tissue engineering triad, suggesting that the two are not modulated 
as separate components, but rather as integrated factors that contribute to the local 
scaffold microenvironment (Fig. 1). Employing raw materials that are natural 
components of tissue’s ECM within scaffolds can act not only as a substrate for cell 
proliferation and attachment, but also a physical signaling environment for 
differentiation.  
 The following sections will highlight four main categories of raw materials that 
are commonly used in recent tissue engineering scaffold strategies: collagen, GAGs, 
bioceramics, and ECM-based materials. Within each section, the most frequently used 
materials for tissue repair and regeneration purposes will be highlighted. For 
organizational purposes, although raw materials have been grouped by material type 
in the following sections, due to the overlap of multiple raw materials in several 
approaches, tables are arranged by the target tissue application. Specifically, raw 
materials used in bone tissue engineering applications in vitro and in vivo can be found 
in Tables 1 and 2, respectively. Strategies employed in cartilage tissue engineering in 
vitro and in vivo can be found in Tables 3 and 4, respectively. Additional target tissue 
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applications can be found in Table 5 and strategies utilizing small intestinal 
submucosa (SIS) can be found in Table 6. 
 
2.3 COLLAGEN 
Collagen is the most prevalent protein in the body, making up approximately 
30 percent of proteins in mammals, and is responsible for both tensile strength and 
structural support in the ECM of many tissues.19 Collagen type I is the most universal 
type, found in bone, skin, tendons, ligaments, and other tissues, and its ubiquity has 
made it one of the most frequently used raw materials in tissue engineering over the 
past decade.20 Hyaline cartilage and nucleus pulposus are the main tissues that 
contain little collagen type I in their native ECM, but are rich in collagen type II.10, 21, 22 
The main advantages of utilizing collagen as a part of a tissue engineering scaffold 
include its intrinsic cell adhesion motif RGD, biocompatibility, and bioresorbability.17, 23 
Questions concerning immunogenicity are considered negligible with the 
development of enzymatic digestion procedures to remove telopeptides.23 Poor 
mechanical properties and rapid degradation are the main drawbacks when 
considering collagen as a scaffold component.17, 20, 23-25 The following sections will 
discuss the use of collagen type I and II in tissue engineering scaffolds and 
applications of collagen as a component of constructs (Tables 1-5). The reader is also 
directed to an extensive review on the use of collagen scaffolds in tissue engineering23 
and collagen nanofibers for bone tissue engineering applications.24  
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Table 1. Recent Applications of Raw Material Strategies for In Vitro Bone Tissue Engineering Applications
Reference(s) Raw material(s)
Additional
material(s) Scaffold formulation Cell type
Growth factor
supplementation
Chan et al.44 Collagen type I (rat) – Microspheres Human and
murine MSCs
–
Koegh et al.46 Collagen type I
(bovine), CS
– Porous composite Human fetal
osteoblasts
TGF-b1
Kruger et al.34 Collagen type I
(bovine)
PLGA Porous matrix Human MSCs –
Shen et al.42 Collagen type I
(porcine), HAp
– Nanocomposite
hydrogel
– –
Sionkowska and
Kozlowska29
Collagen type I,
HAp
– Nanocomposite
hydrogel
– –
Thein-Han
and Xu35
Collagen
type I (rat)
CaP cement,
alginate
Injectable microbead
hydrogel
Human
UCMSCs
–
Wang
and Stegemann40
Collagen type I
(bovine)
Chitosan Composite hydrogel Human MSCs –
Akkouch et al.27 Collagen type Ib,
HAp
PLCL Porous composite Human
osteosarcoma
HEGF
Chicatun et al.57 Collagen
type I (rat)
Chitosan Dense collagen
composite hydrogel
MC3T3-E1 –
Marelli et al.43 Collagen type I (rat) Bioactive glass Composite hydrogel MC3T3-E1 –
Bae et al.80 HA – Hydrogel MC3T3-E1 Simvastatina
Chen et al.81 HA, collagen type Ib PCL Porous matrix hMSC-TERT –
Chen et al.82 HA, collagen type I
(bovine)
Bioactive
glass, PS
Porous composite MC3T3-E1 –
Liao et al.83 HA HA-CPN Injectable,
thermoresponsive
hydrogel
Canine MSCs TGF-b1
Li et al.104 HAp Chitosan, PLLA Porous composite MC3T3-E1 cells –
Liu et al.109 nHAp, collagen
type Ib
PLA Porous composite Rabbit DPSCs BMP-2
Peng et al.107 HAp PLLA Nanofibrous
composite
Rat osteosarcoma
cells
–
Prosecka et al.110 HAp, collagen
type I (bovine)
– Porous composite Porcine MSCs –
Haimi et al.122 TCP PLA, bioactive
glass
Porous composite Human ASCs –
Lee et al.117 TCP, collagen
type I (porcine)
PCL Porous composite MG63 –
Lin et al.131 TCP – Porous matrix – –
Rai et al.118 TCP PCL Porous composite hMSCs –
Yanoso-Scholl et al.123 TCP PLA Porous composite None BMP-2, VEGFa
Yeo et al.120 TCP, collagen
type I (porcine)
PCL Nanofibrous
composite
MG63 –
Zhang et al.126 TCP, collagen
type Ib
– Microfibrous
composite
MG63 –
Honsawek et al.141 SIS, human DBM – Composite matrix Human
periosteal cells
–
Supronowicz et al.155 Human DBM – Porous matrix Human ASPSCs –
Thomas et al.160 Bovine DBM PL Composite matrix Murine MSCs –
Lee et al.156 Human DBM, HAp – Porous composite Human MSCs –
Liu et al.152 pDBM – Porous matrix UCB-BMSCs TGF-b1
Chen et al.153 Bovine DBM Heparin Porous matrix HUVECs VEGFa
Jayasuriya et al.162 Human DBM PLGA Composite film Murine MSCs –
Kang et al.158 Human DBM Fibrin glue Composite glue Porcine SDMSCs –
aDenotes incorporation of the molecules into the scaffold. All other entries indicate the addition of the growth factor to culture medium;
dexamethasone, b-glycerophosphate, and ascorbic acid were considered standard osteogenic medium components and not factored in for
growth factor supplementation.
bCollagen species not specified.
CS, chondroitin sulfate; HAp, hydroxyapatite; HA, hyaluronic acid; TCP, b-tricalcium phosphate; SIS, porcine small intestinal submucosa;
DBM, demineralized bone matrix; pDBM, partially demineralized porcine trabecular bone; PLGA, poly(lactic-co-glycolic acid); CaP, calcium
phosphate; PLCL, poly(lactide-co-e-caprolactone); HA-CPN, hyaluronic acid-g-chitosan-g-poly(N-isopropylacrylamide); PCL, poly(e-
caprolactone); PLA, poly(L-lactic acid); PLLA, poly(L-lactic acid); PL, polylactide; MSCs, mesenchymal stem cells; UCMSCs, umbilical
cord mesenchymal stem cells; MC3T3-E1, murine calvarial osteoblasts; hMSC-TERT, human mesenchymal stem cell–telomerase reverse
transcriptase gene-transduced; DPSCs, dental pulp stem cells; ASCs, adipose stem cells; MG63, human osteoblast-like cells; ASPSCs, adipose-
derived side population stem cells; UCB-BMSCs, human umbilical cord blood–derived mesenchymal stem cells; HUVECs, human umbilical
vein endothelial cells; SDMSCs, skin-derived mesenchymal stem cell–like cells; TGF-b1, transforming growth factor beta-1; HEGF, human
epidermal growth factor; BMP-2, bone morphogenetic protein-2; VEGF, vascular endothelial growth factor.
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Table 3. Recent Applications of Raw Material Strategies
for In Vitro Cartilage Tissue Engineering Applications
Reference(s) Raw material(s)
Additional
material(s)
Scaffold
formulation Cell type
Growth factor
supplementation
Li et al.45 Collagen type I (rat) – Microspheres Human MSCs TGF-b3
Lu et al.26 Collagen type I (porcine) – Sponge Bovine chondrocytes –
Lu et al.33 Collagen type I (porcine) PLGA Porous composite Bovine chondrocytes –
Ng et al.32 Collagen type I, collagen
type II (porcine)
– Porous matrix Porcine MSCs and
murine ECCs
TGF-b1
Ohyabu et al.31 Collagen type I,a
HAp, CS
– Porous composite
sponge
Rabbit MSCs TGF-b3
Yan et al.28 Collagen type I
(bovine), chitosan
Chitosan Composite
hydrogel
Rabbit chondrocytes –
Berendsen et al.36 Collagen type I (rat),
collagen type II
(chicken sternum)
– Hydrogel Goat articular
chondrocytes
–
Zhang et al.67 Collagen type I
(bovine), HA, CS
– Composite
hydrogel
Rabbit articular
cartilage
–
Mueller-Rath
et al.59
Collagen type I (rat) – Dense collagen
hydrogel
Human articular
chondrocytes
–
Chang et al.60 Collagen type II,a CS PCL Coated porous
mesh
Rat chondrocytes –
Francioli et al.61 Collagen type II
(porcine)
– Porous matrix Human articular
chondrocytes
TGF-b1, TGF-b3,
FGF-2
Vickers et al.22 Collagen type II
(porcine), GAG
– Composite
hydrogel
Carpine MSCs FGF-2, TGF-b1
Wu et al.62 Collagen type II (bovine) Exogenous
GAGs
Composite
hydrogel
Human articular
chondrocytes
–
Park et al.77 HA Fibrin Composite
hydrogel
Rabbit MSCs TGF-b1
Fan et al.76 HA, CS PLGA, gelatin Porous composite Rabbit MSCs TGF-b3b
Correia et al.66 HA Chitosan Porous composite Bovine chondrocytes TGF-b3
Nguyen et al.54 CS, HA PEG,
MMP-pep
Multilayered
hydrogel
Murine MSCs TGF-b1
Coburn et al.97 CS PCL, PVAMA,
CSMA,
PEGDA
Fiber–hydrogel
composite
Goat MSCs –
Liang et al.56 Concentrated CS,
collagen type I
(bovine)
– Porous composite Human MSCs TGF-b1, FGF-2
Kinneberg et al.53 CS, collagen type I
(bovine)
– Sponge Rabbit MSCs –
Wang et al.159 Human DBM Gelatin,
fibrin glue
Composite
sponge
Rabbit articular
chondrocytes
–
aCollagen species not specified.
bDenotes incorporation of the protein into the scaffold. All other entries indicate the addition of the growth factor to culture medium;
nonessential amino acids, ascorbic acid, and dexamethasone were considered standard chondrogenic medium components and were not
factored in for growth factor supplementation.
GAG, glycosaminoglycan; PEG, poly(ethylene glycol); MMPs, matrix metalloproteinase–sensitive peptides; PVAMA, poly-(vinyl alcohol)-
methacrylate; CSMA, chondroitin sulfate-methacrylate; PEGDA, poly(ethylene glycol)-diacrylate; ECCs, P19 embryonal carcinoma cells;
FGF-2, fibroblast growth factor-2.  
 
2.3.1 Collagen Type I 
 Collagen type I scaffold formulations have included sponges,25-33 fibers,19, 34, 35 
hydrogels36-43 and microspheres.44, 45 Applications of collagen type I span target areas 
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of bone,27, 29, 34, 35, 40, 42, 44, 46 tendon,19, 47 peripheral nerves,41, 48 cartilage,26, 28, 31-33, 37, 45 skin,25, 
39, 49, 50 and bladder tissue engineering.51 To address limitations associated with 
collagen, researchers have often chosen to use different crosslinking agents and/or 
composites of collagen with other materials.20 In many approaches, blends of collagen 
I with chondroitin sulfate (CS), hyaluronic acid (HA), bioceramics, and synthetic 
polymers have been utilized to enhance mechanical properties, reduce susceptibility 
to degradation, and encourage mineralization.7 Seo et al.52 provided a comprehensive 
review of the reinforcement of collagen and other raw materials by synthetic 
polymers. Akkouch et al.27 presented an interesting approach of employing a 
reinforced natural material scaffold composed of collagen-hydroxyapatite-
poly(lactide-co-ε-caprolactone) (PLCL) for bone tissue engineering (Table 1). In this 
case, PLCL offered a solution to enhance the inherent poor mechanical stability that 
collagen and hydroxyapatite lacked when used without a reinforcing material.27 This 
composite material showed the innovative use of both a synthetic and bioceramic 
material additives to a collagen type I matrix to overcome limitations associated with 
each of the materials when used alone.  
Other strategies have combined collagen with GAGs for additional 
applications. For example, scaffolds of type I collagen and chondroitin-6-sulfate, 
termed in the literature more generally as collagen-GAG or CG scaffolds, represent a 
common raw material blend for bone,46 cartilage,53, 54 tendon,47 and skin38, 55, 56 tissue 
engineering. One particularly innovative raw material technique used a CG core-shell 
fabrication strategy to enhance mechanical integrity while maintaining a highly 
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porous structure.47 The scaffold consisted of a high density CG shell to promote tensile 
strength and a low density CG core scaffold with high porosity (Table 5). This study 
was representative of a scaffold that combined an innovative formulation approach 
and raw materials for tendon tissue engineering.  
Table 4. Recent Applications of Raw Material Strategies For In Vivo Cartilage Tissue Engineering Applications
Reference(s) Raw material(s)
Additional
material(s)
Scaffold
formulation Animal model Highlighted finding
Chang et al.37 Collagen type I
(porcine)
– Hydrogel Lee-Sung miniature
pigs, osteochondral
defect model
Undifferentiated collagen gels
seeded with porcine MSCs
were superior to those that
were differentiated using
TGF-b3 prior to
implantation based on gross
appearance and histological
evaluation after 6 months
Lu et al.26 Collagen type I
(porcine)
– Funnel-like
sponge
Athymic nude mice,
subcutaneous dorsa
model
After 3 weeks, funnel-like
collagen sponges
outperformed control
collagen sponges in cell
number and GAG
production
Lu et al.33 Collagen type I
(porcine)
PLGA Funnel-like
hybrid
sponge
Athymic nude mice,
subcutaneous dorsa
model
Funnel-like hybrid sponges
(collagen type I–PLGA)
outperformed collagen-only
sponges in the expression of
collagen type II and
aggrecan genes after
7 weeks of implantation
Fan et al.76 HA, CS PLGA,
gelatin with
immobilized
TGF-b3
Porous
composite
sponge
New Zealand white
rabbits, full-thickness
osteochondral defect
model
After 8 weeks, TGF-b3-
immobilized scaffolds
seeded with autologous
MSCs promoted significant
cartilage formation when
compared with control
(no TGF-b3)
Yagihashi
et al.164
Bovine DDM – Powder New Zealand white
rabbits, full-thickness
osteochondral defect
model
After 9 weeks, defects filled
with 100mg of DDM had
filled in with hyaline-like
cartilage, with incomplete
cartilage formation in the
control (sham) group
DDM, demineralized dentin matrix.
 
Another method for overcoming the inherent poor mechanical properties of collagen 
included plastic compression of collagen type I hydrogels to produce dense 
collagen.43, 51, 57-59 This approach has been employed for applications in bone,43, 57 
cartilage,59 and bladder51 tissue engineering with favorable outcomes. Chicatun et al.57 
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fabricated a dense collagen and chitosan scaffold that retained an open, 
interconnected pore structure that attempted to mimic the osteoid of native bone 
(Table 1). This strategy demonstrated an excellent example of the use of a raw material 
to mimic not only a component of native bone tissue but also the inherent pore 
structure and ECM structure. The ubiquity of collagen type I in the body and the 
versatility of scaffold formulations have promoted widespread use in tissue 
engineering scaffolds. Relatively new fabrication methods, such as dense collagen 
techniques help to mitigate mechanical limitations without the need for additional 
materials. However, crosslinking and composite strategies still remain the most 
common approach for enhancing construct properties, while maintaining the benefits 
associated with cell adhesion capability of collagen.  
 
2.3.2 Collagen Type II 
Collagen type II has been used much less frequently in raw material strategies 
for tissue engineering constructs, mostly likely due to its presence in considerably 
fewer extracellular matrices of tissues in the body. Scaffold formulations reported 
recently in the literature of collagen type II include hydrogels,21, 36 sponges,22, 60-62 and 
microspheres.14 These scaffolds have been mainly utilized for cartilage22, 36, 60-63 and 
nucleus pulposus21 tissue engineering. Hyaline cartilage and the nucleus pulposus 
have the greatest amount of collagen type II present in their extracellular matrix with 
little to no collagen type I, so this material strategy may be beneficial for these limited 
applications. One group utilized a collagen type I/calcium phosphate layered with an 
!
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interfacial layer connecting to a collagen type II/CS layer to mimic native constituents 
involved in the transition of tissue types at the osteochondral interface.63 Calderon et 
al.21 utilized a similar strategy to formulate a scaffold for nucleus pulposus tissue 
engineering that consisted entirely of raw materials. They used collagen type II and 
hyaluronic acid in a ratio equivalent to the native tissue ECM of the nucleus pulposus 
and noted that with sufficient crosslinking, this raw material scaffold would be a 
potential candidate for regeneration of the nucleus pulposus (Table 5).21 Far fewer 
approaches utilize collagen type II in raw material scaffolds, however, the strategy of 
mimicking native ECM composition has increased its utility in hyaline cartilage and 
nucleus pulposus applications.   
 
Summary 
 Overall, collagen type I has been explored in numerous areas of tissue 
engineering with growing interest in areas of new fabrication techniques and 
composite strategies. Collagen type II, however, has been utilized much less 
frequently and may require more in-depth studies to verify its potential. It is unclear 
whether the limited use of collagen II is due more to its high cost and limited 
availability, the absence of compelling data thus far to support its use, a limited 
awareness of the idea to use collagen II, or a combination of the above. There is no 
question, however, that using collagen I or collagen II can allow for scaffold 
bioresorbability and cell adhesion unmatched by synthetic polymers. 
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Table 6. Recent Tissue Engineering Strategies Utilizing Porcine Small Intestinal Submucosa
Target
tissue Reference(s) Additional material(s)
Scaffold
formulation Biological model(s)
Bone Kim et al.142 – Sponge In vitro: sponges seeded with rat MSCs and cultured
for 14 days
In vivo: sponges seeded with cells and implanted into a
cranial defect model in Fisher rats for 28 days
Honsawek
et al.141
Human DBM Tissue/
composite
matrix
In vitro: scaffolds seeded with human periosteal cells
and cultured for 10 days
In vivo: composites were implanted intramuscularly
into Wistar rats for 42 days
Zhao et al.143 – Hydrated SIS
matrix
In vivo: SIS scaffolds seeded with rabbit MSCs and
implanted into radial bone defects of critical size in
New Zealand white rabbits for 12 weeks
Skin Zhou et al.145 – Hydrated SIS
matrix
In vitro: scaffolds seeded with murine ADSCs and
cultured for 7 days before digestion
In vivo: scaffolds seeded with murine ADSCs and
cultured for 1 week and then implanted into
cutaneous and subcutaneous wound models in C57
mice for 28 days
Nerve Kang et al.144 PLGA Porous
composite
In vivo: composite scaffolds seeded with rat ADSCs
and implanted into complete spinal cord transaction
in Fisher rat model for 8 weeks
Vascular Liu et al.86 Collagen type I–HA–CS
(comparison study
between SIS and
polymer composite)
Tissue scaffold
and polymer
composite
In vivo: SIS and polymer composite scaffolds seeded
with murine ADSCs and implanted into full-
thickness cutaneous defects in C57BL/6 mice for
21 days
Mondalek
et al.87
HA-PLGA
nanoparticles
Porous
composite
In vivo: composite scaffolds implanted into canine
bladder model of Beagle dogs for 10 weeks to
evaluate angiogenic potential
Crapo et al.137 – Gel In vitro: SIS gel seeded with rat neonatal
cardiomyocytes and cultured for 13 days
Okada et al.138 – Gel In vivo: SIS gel injected into infarct cardiac tissue in
NON-SCID mice for 6 weeks
Peng et al.139 – Hydrated SIS
matrix
In vitro: SIS tissue seeded with lamb hair follicle MSCs
and cultured for 14 days under uniaxial strain
conditions
Tan et al.140 – Hydrated SIS
matrix
In vivo: SIS sheets seeded with rabbit MSCs and
implanted to patch infarct myocardial tissue model
in New Zealand White rabbits for 28 days
Urogenital Heise et al.146 – Hydrated SIS
matrix
In vitro: SIS sheets seeded with rat MSCs and subjected
to a period of static culture for 7 days followed by
dynamic culture with cyclic strain for an additional
7 days
Qin et al.147 – Hydrated SIS
matrix
In vitro: SIS sheets seeded with rat intestinal SMCs and
implanted into jejunal interposition model of adult
Lewis rats for 8 weeks
Wu et al.148 – Hydrated SIS
matrix
In vitro: SIS sheets seeded with human UDSCs and
cultured under static and dynamic conditions for
14 days. Cultured sheets were sectioned for in vitro
characterization and implantation
In vivo: precultured SIS sheets were implanted
subcutaneously into the flanks of athymic nude mice
for 1 month
Zhang et al.149 – Hydrated SIS
matrix
In vivo: SIS sheets implanted into abdominal wall
defect model in adult Sprague-Dawley rats for
8 weeks
ADSCs, adipose-derived stem cells; NON-SCID, nonobese diabetic severe combined immunodeficiency; UDSCs, urine-derived stem cells.
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2.4 GLYCOSAMINOGLYCANS 
 Over the past decade, GAGs have emerged as additional raw material strategy 
for multiple tissue engineering applications. Two of the most widely used GAGs 
include HA and CS. HA is well known for its role in the regulation of cell behaviors, 
such as adhesion, proliferation, differentiation and migration.64 However, limitations 
including water solubility, fast resorption, and negative charge have caused 
researchers to adopt specific concentration limits and fabrication methods.65, 66 CS 
functions as a structural component of native ECM and strategies have utilized CS in 
tissue engineered constructs often with additional raw materials, such as HA and 
collagen, respectively.53, 67 The main motivation for blending CS with additional raw 
materials or synthetic polymers lies in its innate capability to be readily water-soluble.9 
Some of the approaches used to overcome weaknesses and incorporate these raw 
materials will be discussed in the following sections. For more in-depth reviews of all 
natural polysaccharides used in tissue engineering, the reader is directed to articles by 
Baldwin et al.6 and Oliviera et al.9 An exceptional review of hyaluronic acid is also 
available from Murano et al.64 Hydrogels that are fabricated from biopolymers have 
also been reviewed extensively, and the reader is directed to articles by Van 
Vlierberghe et al.,68 Slaughter et al.,69 Spiller et al.,70 Hunt et al.,71 and Burdick and 
Prestwich.72 
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2.4.1 Hyaluronic Acid 
HA is the only non-sulfated GAG and is found in the ECM of many tissues in the 
body. HA is well-known for its viscoprotective capabilities and has been used in 
ophthalmology applications for over thirty years.73 Supplementation of HA for synovial 
fluid viscosity in arthritic joints has also been used for over a decade.73 In addition, HA 
interacts with specific protein receptors on the surface of cells, such as CD44 and 
RHAMM, to modulate cell adhesion, proliferation, motility, and other signaling 
cascades.74  For these reasons, HA has been utilized in recent tissue engineering 
strategies for skin,50, 75 cartilage,14, 66, 76-78 bone,79-83 angiogenesis,30, 84-87 meniscus,88 
nerve,41, 89 and nucleus pulposus21, 90 applications. Methacrylated HA that is crosslinked 
to form hydrogels21, 41, 72, 79, 80, 83, 89-91 has been the most common formulation as a tissue 
engineering construct, however, electrospun fibers,92 porous composite coatings and 
sponges have also been tested.91 For an exceptional review on the use of HA in 
cartilage tissue engineering, the reader is directed to Kim et al.91 
Many different strategies have been employed to overcome the fast resorption, 
mechanical integrity, and water solubility of HA. An approach most frequently 
employed for formulating tissue engineering constructs consists of crosslinking HA by 
photopolymerization79, 80, 85, 92-94 or thermal76, 83, 90 mechanisms to form hydrogels in 
which cells can be encapsulated.89, 91 Crosslinking can function to increase mechanical 
strength, while also prolonging degradation of HA.65 Zhang et al.67 engineered a 
hydrogel scaffold by thermal crosslinking for cartilage tissue engineering comprised 
solely of components found in the ECM of cartilage tissue using bovine collagen type I, 
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HA, and CS (Table 3). Freeze drying is a common fabrication method to form 
composite porous matrices containing HA and other materials for tissue engineering 
constructs.66, 75, 78, 81, 82, 88, 95 Zhang et al.75 assembled highly macroporous composite 
scaffolds of HA and gelatin for soft tissue engineering applications using a freeze 
drying technique (Table 5). It is also important to note that HA must be utilized in 
relatively low concentrations to avoid limited cell adhesion that can occur at higher 
concentrations due to its negative charge.66 Fabricating composites with HA and 
neutral or positively charged materials can help mitigate this charge limitation. One 
specific example of a composite HA strategy by Sundararaghavan and Burdick92 
created dual-gradient, electrospun fiber scaffolds incorporating HA with RGD peptide 
sequences to promote cell adhesion. This example demonstrated both an exceptional 
raw material and scaffold formulation approach, while also providing a recent 
example of a gradient scaffold that incorporated a raw material.92  
The versatility and biocompatibility of HA has attracted attention for the 
delivery of growth factors and other biological molecules in tissue engineering 
scaffolds.18 Recent approaches have included the delivery of signaling molecules such 
as simvastatin,80 vascular endothelial growth factor (VEGF),79, 84 platelet derived growth 
factor (PDGF),84 transforming growth factor beta-1 (TGF-β1),77 transforming growth 
factor beta-3 (TGF-β3),76 bone morphogenetic protein-2 (BMP-2),79 phosphatidylserine 
(PS),78 and fibronectin.85 Bae et al.80 fabricated HA hydrogels loaded with simvastatin 
prior to photocrosslinking to entrap the molecule within the entangled gel matrix. 
Most researchers utilized the ability to control molecule delivery within HA scaffolds 
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by modulating properties such as molecular weight, crosslinking, and scaffold 
formulation, accordingly. Overall, the ubiquity of HA in the body has been mirrored by 
tissue engineers in a wide variety of applications. Chemical modifications, crosslinking, 
and blending of HA with other materials are the most common methods used to apply 
this raw material for regenerative constructs and innovative approaches continue to 
be developed for several different applications. 
 
2.4.2 Chondroitin Sulfate 
CS is a GAG that is found mainly attached to proteoglycans in connective tissue 
matrices or conjugated to proteins such as aggrecan in articular cartilage.6 The 
different forms of CS depend on the sulfation site, typically at either the 4 or 6 carbon, 
however, chondroitin-6-sulfate is used in tissue engineering most frequently.6 The 
presence of CS in native tissues has led to its use in cartilage,31, 53, 54, 56, 60, 76, 96, 97 skin,38, 50, 
56, 98 bone,46, 99, and blood vessel55, 86 tissue engineering scaffolds. In addition to the 
aforementioned CG scaffolds, CS has been blended with many synthetic polymers and 
raw materials. A study by Kinneberg et al.53 employed CS within a collagen hydrogel to 
investigate a potential increase in the linear stiffness of the gel constructs by helping 
to link discontinuous collagen fibrils in the gel network. Nyugen et al.96 designed a 
three-layer hydrogel scaffold with varying compositions of CS, HA, and polyethylene 
glycol (PEG) to simulate the mechanical properties of each zone of articular cartilage. 
This triphasic construct demonstrated another approach for mimicking native tissue 
using raw materials and synthetic polymers in a spatially varying scaffold architecture. 
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Additionally, Coburn et al.97 pioneered a fiber-hydrogel composite fabricated with 
methacrylated poly(vinyl-alcohol) and chondroitin sulfate fibers encapsulated within a 
PEG hydrogel. The fibers were hypothesized to mimic the nature of native protein 
networks, while the hydrogel served to simulate the polysaccharide-based ground 
substance that are both characteristic of the ECM of tissue.97 Liang et al.56 investigated 
the differences in scaffold properties with varying concentrations of collagen and CS in 
CG scaffolds for both cartilage and skin tissue engineering. This strategy showed the 
tunability of CG scaffolds with respect to water uptake, pore size, and elastic modulus 
to tailor properties for necessary properties for each target tissue.56 A combination of 
HA, CS, and gelatin were fabricated into tri-co-polymer sponges and incorporated into 
a poly(lactic-co-glycolic acid) (PLGA) framework.76 Additionally, the scaffolds were 
loaded with immobilized transforming growth factor beta-3 (TGF-β3) and implanted in 
full-thickness cartilage defects in New Zealand white rabbits (Table 4).76 Wang et al.50 
employed a strategy of using solely raw materials to mimic the ECM of the dermis for 
skin tissue engineering grafts. The scaffold matrix consisted of collagen, CS, and HA 
with different ratios of each component, and were tested for optimal construct 
properties (Table 5).50 This study, along with several others, embodied the emerging 
raw material approach for tissue engineering scaffolds. Overall, CS can be used to 
enhance mechanical integrity of a scaffold while also helping to mimic native ECM in 
connective tissues as well as articular cartilage. Skin, cartilage, and bone tissue 
engineering have utilized CS most frequently, however, this raw material is poised to 
become an effective scaffold component in many other target tissue applications. 
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Summary 
 The use of GAGs in tissue engineering strategies continues to become more 
sophisticated in fabrication techniques and raw material approaches. The combination 
of HA and CS has recently became evident as a conceivable raw material approach in 
both cartilage and skin tissue engineering applications. As the use of these native 
molecules continues to spread to additional applications, the potential of achieving 
clinical success using these raw materials appears limitless. 
 
2.5 BIOCERAMICS  
 Mineralization of scaffolds plays a major role in bone as well as osteochondral 
interface tissue engineering. Calcium phosphate ceramics are biocompatible and their 
ability to be bioactive in the body stems from their similarity in composition and 
structure to the mineral phase of bone.100 Some of the advantages of using 
bioceramics as part of a tissue engineering scaffold include increased mechanical 
strength, biocompatibility, and osteoconductivity.3, 100 However, the brittle nature and 
slow degradation times of these ceramics can prove unattractive for tissue 
engineering constructs.3 Researchers have blended synthetic polymers and/or several 
of the aforementioned raw materials with bioceramics to help to overcome the 
limitations of calcium phosphate materials for bone and cartilage tissue engineering 
constructs. Additionally, advances in fabrication methods to produce highly 
macroporous bioceramic scaffolds has helped to facilitate faster degradation rates. 
Two of the most widely used bioceramic materials in tissue engineering scaffolds, 
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hydroxyapatite (HAp) and beta-tricalcium phosphate (β-TCP), will be highlighted in 
the following sections. For comprehensive reviews on ceramic materials and their use 
in tissue engineering, the reader is directed to articles by Dorozhkin et al.,100 Li et al.,3 
and Porter et al.101  
 
2.5.1 Hydroxyapatite 
 Hydroxyapatite (HAp) is the main inorganic phase of bone and these crystals 
bind to collagen type I fibers in the ECM of native tissue.101 Since collagen regulates 
the size and orientation of the HAp crystals, the structural relationship of this organic-
inorganic matrix contributes largely to the mechanical properties of bone.3, 101 In its 
non-porous and highly crystalline form, HA is known to remain unchanged for 5-7 
years in the body with little to no resorption.100 However, most tissue engineering 
strategies have incorporated synthetic HAp into porous scaffolds along with raw 
materials and/or synthetic polymers to best mimic the native ECM and properties of 
bone. The need for blends of polymeric materials with HAp stems from the brittle 
nature of HAp as a macroporous scaffold, and biopolymer incorporation can help to 
tune the elasticity of the scaffold as well as the degradation properties.101 Texiera et 
al.102 employed a raw material blend consisting of a collagen type I coating on a 
porous HAp matrix to mimic native bone composition and aid in cell adhesion. As a 
composite matrix, this material combination provided a microstructure that 
attempted to mimic native bone and provided a suitable microenvironment for new 
bone formation in vivo (Table 2).102 Zhou et al.103 demonstrated a similar strategy by 
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formulating bi-layered osteochondral scaffolds that consisted of a collagen type I layer 
on the top of the construct with a collagen/HAp layer on the bottom to imitate the 
transition from cartilage to bone tissue structure at this interface. The biphasic 
scaffolds were seeded with human mesenchymal stem cells and cultured separately in 
chondrogenic and osteogenic medium (Table 5).103 Li et al.104 constructed a composite 
of poly(L-lactic) acid (PLLA), chitosan, and HAp microspheres as a hybrid bone tissue 
engineering composite and studied the cellular response to these constructs in vitro 
using murine calvarial osteoblasts (Table 1). Approaches by each of these groups 
demonstrated the growing tendency of raw materials to be utilized as building blocks 
in bone tissue engineering scaffolds.  
A longstanding debate in the bone tissue engineering literature is the use of 
micro versus nanoscale HAp in constructs.3, 17 Employing a nanoscale HAp approach is 
hypothesized to allow the scaffold to better mimic the nanostructure of bone and 
encourage the differentiation of stem cells.105, 106 Peng et al.107 investigated the use of 
microscale versus nanoscale HAp powders incorporated with PLLA electrospun fibers. 
After a 10-day culture period, the composite scaffolds containing microscale HAp 
particles showed the best cell performance, but both particle sizes exhibited 
satisfactory cell viability and signaling.107 Nanoscale HAp formulations have included 
nanoparticles108-110 or nanofibers111, 112 in combination with other materials. Zhang et 
al.112 created a nanofibrous composite scaffold of HAp, collagen type I, and chitosan to 
mimic the nanostructure of native bone. A similar nano-composite approach was 
employed by Liu et al.109 for treatment of periodontal bone defects using nano HAp, 
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collagen type I, and poly(lactic acid) (PLA). Overall, collagen type I has been one of the 
most widely utilized raw materials for creating HAp composites due to its ability to 
promote cell adhesion, which is limited in pure HAp constructs (Table 1). An 
exceptional review by Wahl et al.113 detailed collagen-HAp composites for bone 
regeneration. The results of the debate between micro or nanoscale HAp formulations 
may suggest the need for additional studies to examine multiple size ranges 
simultaneously or differences that exist between fabrication methods that can help 
enhance mechanical integrity while also modulating cell differentiation. 
 
2.5.2 Beta-Tricalcium Phosphate 
 The tunability of resorption rates of β-TCP has attracted great attention within 
the bone and osteochondral interface tissue engineering communities.101, 114 While β-
TCP can be resorbed too quickly for some applications in vivo, the ability to blend the 
material with polymers and control the granule size115 offers methods to modulate 
resorption rate while utilizing the advantage for tissue in-growth when compared to 
the prolonged degradation of crystalline HAp. Synthetic polymers such as poly(ε-
caprolactone) (PCL),116-120 PLA,121-123 poly(glycolic acid) (PGA),124 and PLGA125 are used 
most often to fabricate composite scaffolds with β-TCP. The main drawback of 
composites with β-TCP and synthetic polymers is poor cell attachment and 
proliferation. However, collagen,117, 120, 126 gelatin,127, 128 and hyaluronic acid129 have also 
been employed with β-TCP and/or synthetic polymers to aid in cell adhesion and 
viability. Yeo et al.120 presented an innovative approach composed of a PCL/β-TCP 
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composite embedded in collagen nanofibers to create a hierarchical structure similar 
to native bone. Niyama et al.130 formulated an osteochondral scaffold using a β-TCP 
porous block covered with a scaffold-free chondrocyte matrix to induce both types of 
tissue formation. Tadokoro et al.128 utilized a gelatin and β-TCP sponge loaded with 
BMP-2 in an in vivo subcutaneous model and observed the presence of new bone 
formation.  
 The microscale versus nanoscale debate has been investigated using powders 
of β-TCP, although the issue is much less controversial than that of HAp. Lin et al.131 
found that nanoscale β-TCP ceramics degraded slower than those fabricated from 
microscale powders. Furthermore, ceramics made from nanoscale β-TCP had twice the 
mechanical strength of those fabricated from microscale powder, and the nanoscale 
β-TCP ceramic reached a compressive strength in the upper range of native cancellous 
bone.131 The combination of mechanical properties and fast resorption of β-TCP made 
from nanoscale powder provide tissue engineers another attractive bioceramic 
formulation option. Another group investigated granule size and morphology of β-
TCP granules in a subcutaneous rat model (Table 2) and found that the greatest 
vascularization occurred in the group with polygonal morsel-shaped granules ranging 
from 63 to 250 microns in size.115 Depending on defect size, healing time, and/or 
target application of the bone tissue engineering construct, the size and shape of β-
TCP particles used in the raw material strategy must be considered and characterized.  
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Summary 
 Overall, the raw material approach to use of bioceramics in bone tissue 
engineering constructs appears to be shifting more away from hydroxyapatite and 
more toward β-TCP due to the ability to finely tune resorption rates to match newly 
forming bone and allow for incorporation of the scaffold into new bone tissue 
(summarized more in-depth in the discussion section). HAp may still be an effective 
raw material strategy in cases where new bone formation is expected to take more 
time. Advances in particle size and formulations of each bioceramic material has 
allowed for many new insights into considerations for fabricating bone tissue 
engineering scaffolds. 
 
2.6 ECM-BASED MATERIALS 
 In addition to native ECM components, raw materials include those derived 
from mammalian tissue, which have been used in several tissue engineering 
applications from skin to heart valves.132-135 Decellularized matrices, such as small 
intestinal submucosa (SIS), as well as heart valves and arteries, are additional sources 
of collagen and endogenous proteins.132 Demineralized bone matrix (DBM) and 
decellularized cartilage are additional ECM-based strategies for retaining organic 
components of native tissue, while removing cells and/or mineralized crystals. Both 
decellularizing and demineralizing strategies can potentially weaken mechanical 
integrity of the matrix. However, many approaches have been employed to modulate 
mechanical stability of SIS and DBM. The following sections will review the use of SIS, 
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DBM, and decellularized cartilage as components of tissue engineering scaffolds and 
strategies to blend each with additional materials or cells for enhanced properties. 
 
2.6.1 Small Intestinal Submucosa (SIS) 
 Of all the potential sources, porcine small intestinal submucosa (SIS) has been 
one of the most studied and utilized ECM-based raw materials in a wide variety of 
applications.132, 135 Studies have shown that SIS contains over 90% collagen by dry 
weight, with a majority being collagen type I.136 Depending on the type of 
decellularization method used, SIS can maintain GAGs and growth factors present in 
the native tissue.132, 135 In addition to these native ECM molecules, the collagen fiber 
orientation that is maintained after the decell process has also attracted attention.132 
Both of these inherent properties have sparked strategies employing SIS as scaffolds in 
the fields of cardiovascular,137-140 bone,141-143 nerve,144 soft tissue,86, 87, 145 and 
urogenital146-149 tissue engineering (Table 6). Currently, SIS is FDA approved for several 
urogenital applications, including hernia repair.132 The presence of aligned collagen 
fibers and endogenous growth factors remaining in the acellular SIS matrix has 
sparked interest within the bone tissue engineering community as well. Kim et al.142 
and Honsawek et al.141 showed that SIS scaffolds promoted new bone formation in a 
rat model. Zhao et al.143 found similar results in a rabbit model when SIS was seeded 
with mesenchymal stem cells. Composite scaffolds fabricated with SIS and synthetic 
polymers or other raw materials have also been employed. Mondalek et al.87 utilized all 
three types of materials by fabricating a SIS scaffold combined with hyaluronic acid-
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poly(lactide-co-glycolide) (HA-PLGA) nanoparticles to enhance angiogenesis in the 
implanted scaffold when compared to SIS only (Table 6).  
 Urinary bladder matrix as well as heart valves and arteries from both 
xenogeneic and allogeneic sources have also been used in several other 
applications.150 For a more comprehensive review on decellularized matrices and their 
role in tissue engineering, the reader is directed to articles by Badylak et al.,132 Hoshiba 
et al.,135 and Piterina et al.136 Overall, utilizing SIS may offer a new dimension to raw 
material scaffolding by inherently combining aligned collagen fibers with remaining 
GAG molecules and growth factors. This complex tissue arrangement presents a 
suitable option for many different tissue engineering applications. 
 
2.6.2 Demineralized Bone Matrix (DBM) 
Demineralized bone matrix (DBM) mimics the strategy behind SIS, and has 
been studied for over 3 decades for use in bone grafting procedures.151 DBM is 
formulated through acidic washing and defatting of human allograft cortical bone, 
which leaves an acellular organic matrix that mimics the microstructure of bone 
tissue.151 Native concentrations of organic materials as well as mechanical integrity 
following the demineralization process are directly proportional to the extent of acidic 
washing.152 Therefore, as more mineral is removed, the mechanical properties weaken 
and the presence of organic components decreases.152 Nevertheless, the presence of 
organic components and proteins has led to the use of DBM in both bone and 
cartilage tissue engineering solutions. After the demineralization process, the 
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remaining acellular matrix is composed mainly of collagen with associated bone 
morphogenetic proteins (BMPs) and GAGs, which is an osteoinductive network that 
can aid in cell attachment, migration, and differentiation.153 However, the inherently 
poor mechanical performance of DBM, along with the variance in quality and 
concentration of the organic materials from donor to donor, present barriers for 
utilizing DBM as a single-component construct.151 To address these limitations and 
construct DBM composite constructs, studies have seeded DBM with stem cell sources 
or blended DBM with both synthetic and raw materials. Researchers have used DBM as 
a sole scaffold component in conjunction with seeded umbilical cord blood-derived 
mesenchymal stem cells (UCB-MSCs)152 and adipose-derived stem cells (ADSCs).154, 155 
Combination of DBM with additional raw materials such as SIS,141 HAp,156 and β-TCP157 
as well as fibrin glue,158, 159 and heparin153 have been employed in bone and cartilage 
tissue engineering. In addition, blends of DBM with synthetic PLA,160 reverse-thermo 
responsive polymers,161 and PLGA162 allow for increased stability and modulation of 
mechanical properties.163 Demineralized dentin matrix (DDM) has also gained 
attention for use in osteochondral tissue engineering. As an example, Yagihashi et 
al.164 investigated the potential of DDM to promote osteochondral regeneration in full-
thickness cartilage defects of New Zealand white rabbits and observed the formation 
of hyaline-like cartilage and new bone formation (Table 4). Both DBM and DDM can 
serve as effective raw materials to be incorporated into both bone and tissue 
engineering scaffolds without the need for additional exogenous growth factors or 
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cytokines. Endogenous organic components allow these raw materials to signal 
surrounding cells and tissue in ways unmatched by purely synthetic scaffolds. 
 
2.6.3 Decellularized Cartilage 
 One scarcely explored tissue in the area of ECM-based materials is the notion of 
decellularizing hyaline cartilage. In theory, acellular hyaline cartilage would be 
expected to provide a scaffold rich in collagen type II, aggrecan, and endogenous 
growth factors following the decellularization process. Some groups have attempted 
to render hyaline cartilage acellular as an intact explant,165, 166 while others have sliced 
or shattered explanted cartilage prior to this process due to the compact nature of 
cartilage tissue that does not allow complete penetration of decellularization 
solutions.165, 167-169 Once the tissue had all of the cellular components removed, the 
remaining cartilage powder or solution was freeze dried to obtain an acellular, porous 
matrix.167, 168 Gong et al. made a sandwich model of porcine acellular cartilage sheets 
with porcine chondrocytes seeded in between each layer of cartilage sheets.169  This 
raw material strategy appears to have potential in the area of ECM-based materials, 
but will warrant future investigation both in vitro and in animal models. 
 
Summary 
 ECM-based matrices offer a distinct advantage of retaining the composition of 
native materials and proteins as well as their inherent spatial arrangements in some 
cases. Both SIS and human DBM are FDA approved for clinical applications.132, 170 
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Composites utilizing ECM-based materials may also have the potential to translate into 
the clinical setting considering all of the current research attempting to develop these 
raw material hybrids. 
 
2.7 BIOACTIVE SIGNALING OF RAW MATERIALS 
 In addition to providing building blocks for fabricating tissue engineering 
scaffolds, raw materials also hold the potential to present signals to cells. As previously 
mentioned, biomaterial-based signaling can arise from physical, chemical, adhesive, 
and mechanical properties of the construct. While many have exploited the inherent 
adhesive RGD peptide present in collagen, many others have examined the signaling 
potential of other raw materials used in tissue engineering constructs. Park et al.77 
investigated the chondrogenic potential of HA/fibrin glue composite hydrogels with 
encapsulated rat mesenchymal stem cells (MSCs) when treated with or without TGF-
β1. Results suggested that treatment with exogenous growth factors was not essential 
for chondrogenic differentiation of rat MSCs in the HA-fibrin glue gel.77 The authors 
hypothesized that the chondroinductive signaling potential of this composite gel 
most likely stemmed from the interaction of cells with the scaffold ECM via integrins 
on the cell surface.77 This interaction was thought to induce intracellular signaling for 
regulation of many cell functions, including differentiation and matrix synthesis.77 
Another study aimed to elucidate the osteoinductive potential of collagen type I/HAp 
scaffolds for bone regeneration.110 The porous composite constructs were seeded with 
porcine MSCs and cultured for 28 days. Results demonstrated osteogenic 
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differentiation of seeded MSCs by relative gene expression analysis using common 
osteogenic markers.110 These studies suggested that mimicking the ECM components 
of native tissue may be a suitable alternative for the promotion of bioactive signaling 
without the addition of exogenous proteins. Similarly, ECM-based materials also offer 
evidence of bioactive signaling potential that stems from inherent native materials 
and growth factors. For example, Kim et al.142 compared the regenerative potential of 
rat MSCs seeded on either a PGA mesh or an SIS sponge to repair full thickness 
bilateral bone defects in rat crania. SIS sponges showed significantly greater new bone 
regeneration when compared to PGA meshes 4 weeks after implantation.142 
Additionally, DBM/fibrin glue scaffolds have been investigated for osteoinductive 
capability with skin-derived mesenchymal stem cell–like cells (SDMSCs).171 After 4 
weeks of culture, osteogenic differentiation was confirmed by relative gene expression 
and flow cytometry.171  
Overall, raw materials offer bioactive signaling potential that is unmatched by 
synthetic biomaterials. Optimization of raw material components and fabrication 
methods may alleviate the need to supplement tissue engineering scaffolds with 
immobilized or solubilized growth factors.  
 
2.8 DISCUSSION 
 Integration of two components of the tissue engineering triad—scaffolds and 
signals—can be accomplished by utilizing raw material strategies in tissue 
engineering constructs. Raw materials can present physical, chemical, adhesive, and 
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mechanical cues to cells without the addition of immobilized or solubilized bioactive 
molecules. Moreover, collagen, GAGs, and bioceramics can be blended into 
composites using additional synthetic polymers and/or other raw materials based on 
the desired scaffold properties. Kruger et al.34 characterized the ability of type I 
collagen to mineralize in comparison to PLGA when seeded with human 
mesenchymal stem cells (hMSCs) subjected to osteogenic media. Collagen scaffolds 
mineralized within 8 weeks of culture, while PLGA scaffolds displayed mineralization 
after 12 weeks.34 Time differences were ultimately attributed to degradation of PLGA, 
which ultimately changed the matrix rigidity, porosity, scaffold architecture, and pH 
balance that can disrupt cell signaling in the local microenvironment. These results 
highlight an important distinction between bioresorbable and biodegradable tissue 
engineering constructs. Bioresorbable scaffold materials are generally raw materials 
that the body is able to recognize and incorporate into surrounding tissue. However, 
biodegradable scaffolds tend to break down in the body over time, creating 
alterations in the local microenvironment and microstructure of the scaffold that may 
adversely affect cell-biomaterial interactions. Arguably, the ability of a scaffold to 
integrate into surrounding tissue is one of the most crucial interactions that governs 
the success of the implanted construct.172 While both synthetic polymers and the 
aforementioned raw materials possess distinct strengths and weaknesses, 
bioresorbability of scaffolds in vivo is certainly a crucial aspect of scaffold fabrication 
and development. 
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 Additionally, selection of the most appropriate raw materials for the target 
tissue remains another important, yet controversial issue. While most researchers tend 
to utilize raw materials that are present in the native ECM, cartilage tissue engineering 
solutions tend to conflict between the selection of type I versus type II collagen (Table 
3). Several raw material approaches utilize collagen type I to regenerate articular 
cartilage,26, 28, 31, 33, 37, 45, 53, 56, 78 despite the well known fact that the collagen of hyaline 
cartilage is predominately type II rather than type I. Studies by Berendsen et al.36 and Ng 
et al.32 attempted to address this raw material debate. Berendesen et al.36 found that 
chondrocyte-mediated contraction occurred only on collagen type I gels but not on 
collagen type II gels, allowing chondroctyes to maintain their phenotype on collagen 
type II gels, which confirmed by relative gene expression of matrix proteins and matrix 
metalloproteinases. Contraction seemed to be a contributing factor to the 
dedifferentiation of chondrocytes in the case of collagen type I gels.36 The authors 
acknowledged that their results pointed toward collagen type II as the material of 
choice for cartilage tissue engineering, however, whether this outcome occurred 
because type II collagen presented a superior cell-biomaterial response or a catabolic 
response of cells to reorganize and produce their own collagen type II has yet to be 
determined.36 However, raw material strategies using collagen type II to mimic the 
native ECM have been employed by other groups with similar success.22, 53, 61 
Contrasting data were obtained in a study by Ng et al.32 where no difference was found 
between the effects of collagen type I and type II gels on mesenchymal stem cell 
proliferation and contraction. It is important to note, however, that differences in cell 
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type, seeding density, seeding technique, and crosslinking method could all 
contribute to the discrepancy between these studies. An additional study examining 
two-dimensional culture of chondrocytes on collagen type II versus aggrecan-coated 
polystyrene found that aggrecan coated surfaces best retained chondrogenic 
phenotype over four passages and collagen type II surfaces tended to induce loss of 
chondrogenic phenotype.173 Logically, collagen type II would appear as the raw 
material of choice for articular cartilage scaffolds, but future studies examining both 
collagen type II and aggrecan will be necessary to confirm the most appropriate 
chondroinductive raw material for cartilage applications. 
 A similar debate exists in the bone tissue engineering community involving the 
choice between HAp and β-TCP as scaffold components. Rojbani et al.174 examined the 
differences in osteoconductivity of HAp and β-TCP microparticles. The particles were 
loaded into calvarial defects in rats and supplemented with and without simvastatin. 
Results concluded that β-TCP proved to be a superior osteoconductive scaffold, 
resulting in greater bone formation compared to HAp, and the addition of simvastatin 
tended to increase bone regeneration in both of the bioceramic scaffolds. The authors 
attributed the success of β-TCP to faster degradation, which allows for a synchronized 
equilibrium between particle degradation and new bone formation.174 No composite 
scaffolds incorporating either material were used in this study, however, investigation 
of hybrid materials containing both HAp and β-TCP would be needed to resolve the 
conflicting strategies of these materials, since these ceramics are not frequently used 
as sole scaffold components. In addition, exploration of each materials’ 
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osteoconductive potential in a nanoparticle format would also be necessary. 
Ultimately, the ability of β-TCP to resorb much more quickly than HAp can provide an 
appealing solution for hastened bone in-growth. 
  Finally, trends in FDA approved tissue engineering scaffolds suggest that many 
areas of tissue engineering have failed to conquer the translational barrier from 
laboratory benches to clinical solutions. Healon® and Synvisc® are examples of HA 
formulations used clinically for ophthalmologic and orthopedic applications, 
respectively.73 Human allograft DBM products, such as Allomatrix®,170 DBX®,170 
Puros®,175 and Grafton®171 are also commercially available. Healos FX®, Collapat II®, and 
Biostite® are collagen type I-based medical products used clinically for various 
applications.136 However, most attribute the failure of many other tissue engineering 
strategies to lie in the distinction between medical devices and combination products, 
respectively.176, 177 Combination products often employ the use of biologics—cells, 
drugs, or growth factors—and must be proven in animal studies and a series of three 
clinical trials, likely spanning over 8 years before approval.177-179 Medical devices do not 
contain biologics and can often be classified as a Class II device or under 510k 
approval (depending on application), alleviating the need for the three phases of 
clinical trials.176, 178 Raw materials such as collagen, SIS, and human DBM contain 
endogenous growth factors and adhesive cues to aid in signaling, without the 
addition of biologics to the scaffold. Therefore, raw materials could provide a method 
for translating effective tissue engineering scaffolds to the clinic without all of the 
additional associated cost and time associated with combination products. 
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 In summary, raw materials present a crucial subset of biomaterials for tissue 
engineering scaffolds. It is no coincidence that industry has already been using raw 
materials such as hyaluronic acid, collagen, and DBM in their regenerative medicine 
products. Quite simply, industry employs these materials because they produce 
results, although academia may be able to contribute more sophisticated and more 
effective designs by being more in tune to this classification of materials in our design 
strategies. Collagen, GAGs, and bioceramics can modulate cell-biomaterial interactions 
and provide building blocks to give tissues a jump start in the regeneration process. 
Many strategies have incorporated raw materials in constructs with exact ratios of 
these components in native tissue. However, a much larger subset of tissue 
engineering approaches rely on the tunability and predictability of synthetic polymer 
scaffolds. Studies suggest that composite materials may be the best method for 
combining both schools of thought. In the ongoing quest to find “perfect” tissue 
engineering scaffolds, it is essential that researchers look to the composition and 
structure of native tissue for material selection and design inspiration. 
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CHAPTER 3: Decellularized cartilage as a chondroinductive material for 
cartilage tissue engineering 
 
 
CHAPTER PURPOSE:  
 The purpose of this chapter was to determine the feasibility of decellularized 
cartilage (DCC) as a raw material for cartilage regeneration applications. This consisted 
of 3 study phases: 
• Decellularization 
• Material Characterization 
• Cell Response 
At each phase, methods and results are detailed in the following sections. This chapter 
is written in the format of a manuscript for the possibility of future submission. A 
preliminary conclusion long with future recommendations are also given. 
 
3.1 ABSTRACT 
 Components found within the extracellular matrix (ECM) have emerged as an 
essential subset of biomaterials for tissue engineering scaffolds. In the present study, 
decellularized cartilage (DCC) fragments were developed to be utilized as a raw 
material scaffold or scaffold component. Bovine articular cartilage was decellularized 
and examined for removal of cellular material and preservation of native 
glycosaminoglycans (GAGs). 99% of cells were removed, while over 87% of native 
GAGs remained following decellularization. Further processing to produce a fine 
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powder of DCC and characterize particle size and chemical composition were 
performed. Transmission electron microscopy (TEM) revealed a dry DCC particle size of 
25-30 nm and only minor composition discrepancies existed between native and DCC 
specimens as confirmed by Fourier transform infrared spectroscopy (FTIR). A pellet 
culture study was used to examine gene expression in rat bone marrow stem cells 
(rBMSCs). Gene expression analysis of chondrogenic markers showed a two-fold 
increase in collagen type II expression and a three-fold increase in Sox9 expression in 
pellets supplemented with DCC powder versus control (blank) cell pellets. An 
encapsulation study revealed that supplementing rBMSC-encapsulated agarose 
hydrogels with 10 mg DCC/mL or 100 mg DCC/mL agarose helped hydrogels maintain 
similar DNA content to initial values (week 0) over a 3-week culture period, while gels 
containing no DCC lost over half of their initial DNA content over the same culture 
period. Overall, DCC may be a new chondroinductive material that can provide 
microenvironmental cues and signaling to promote stem cell differentiation in 
cartilage regeneration. This study is the first of its kind to assess stem cell gene 
expression in response to DCC, grind DCC into a nanopowder to allow incorporation 
of this raw material into many different scaffold formulations, and perform complete 
cell removal (>97%), while retaining close to native GAG concentrations. 
 
3.2 INTRODUCTION 
 Osteoarthritis is expected to affect over 100 million adults in the United States 
by the year 2020 creating an economic burden of over $100 billion on the healthcare 
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system.180 Cartilage defects, whether caused by osteoarthritis, joint trauma, or other 
disease, have provoked a wide variety of tissue engineering scaffold strategies in 
recent years. Traditionally, cartilage tissue engineering scaffolds have utilized 
synthetic polymer components to form hydrogels or other porous matrices. 
Poly(ethylene glycol) diacrylate (PEG-DA) and poly(D,L-lactic-co-glycolic acid) (PLGA) 
are some of the most common synthetic polymers used in cartilage regeneration 
scaffolds.168 However, the main disadvantage of synthetic biomaterials for cartilage 
tissue engineering is their inherent lack of bioactive signaling molecules or 
microenvironmental cues to direct stem cell differentiation. 
Collagen, glycosaminoglycans (GAGs), and other ECM-based matrices are key 
examples of ‘‘raw materials’’ that can be incorporated into scaffolds for a wide variety 
of applications. For cartilage tissue engineering, the most widely used raw material 
building blocks for scaffolds include collagen type I,26, 28, 31-33, 36, 59, 67, 86 collagen type II,22, 
60-62 hyaluronic acid,66, 76, 77, 90 and chondroitin sulfate.50, 53, 54, 56, 97 Cartilage ECM is made 
up of approximately 70% water (w/w), 20% collagen (types II, IX and XI), and 10% 
aggrecan. 181 The ECM-rich nature of hyaline cartilage – volume ratio of 95% matrix to 
5% chondrocytes  – makes it an ideal candidate for decellularization.182  
Utilizing decellularized cartilage as an ECM-based raw material, however, has 
scarcely been investigated in the literature. In theory, acellular hyaline cartilage would 
be expected to provide a scaffold rich in collagen type II, aggrecan, and endogenous 
growth factors following the decellularization process. Some groups have attempted 
to decellularize cartilage as an intact tissue block,165, 166 while others have shattered or 
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cut thin slices of the tissue to allow for better penetration of solutions during the 
decellularization procedure.167-169, 182 The majority of studies have investigated 
chondrocyte viability and gene expression in response to decellularized cartilage 
tissue with the goal of maintaining chondrogenic phenotype.182, 183 
The goal of the present study was to investigate the development of 
decellularized bovine hyaline cartilage as a potential chondroinductive raw material, 
both alone and as a scaffold component.  As mentioned previously, current work in 
the literature has only examined the use of DCC to help main chondrogenic 
phenotype of chondroctyes; however, this study aimed to examine preliminary 
chondroinductivity of DCC, i.e., the ability of DCC to provide a microenvironment that 
would induce chondrogenic differentiation of bone marrow stem cells. A previous 
study by Cheng et al.184 examined the potential of porcine articular cartilage to induce 
chondrogenesis in adipose-derived stem cells using gene expression analysis. The 
distinction between this work and the present study lies in the decellularization 
process. This group minced cartilage into fragments and lyophilized immediately to 
form a porous scaffold – no decellularization techniques were performed and no 
confirmation of cellular removal was addressed.184 Another study used human articular 
cartilage and examined chondrogenic induction of bone marrow stem cells.168 
However, this group used immunohistochemistry to stain for chondrogenic markers 
and did not quantitatively evaluate gene expression.168 In addition, growth factors 
(transforming growth factor beta-1 (TGF-β1) and basic fibroblast growth factor (bFGF)) 
were used to influence chondrogenic differentiation in this study.168 
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In the present work, however, tissue decellularization was performed and 
confirmed prior to use as scaffolds. Bovine articular cartilage was harvested and 
decellularized and examined for DNA content, GAG content, chemical composition 
before/after decellularization, and particle size following grinding into a fine powder. 
DCC was then incorporated into agarose hydrogels along with rat bone marrow stem 
cells (rBMSCs) to examine cell proliferation. Then, the DCC tissue pieces were placed in 
pellet culture to determine their influence on rBMSC gene expression. No growth 
factors were used in culture medium this work to determine the influence of DCC 
alone as a chondroinductive material. To the best of our knowledge, this is the first 
time that stem cell response to DCC, in terms of gene expression response to 
decellularized hyaline cartilage tissue, has been characterized. 
 
3.3 MATERIALS AND METHODS 
3.3.1 Tissue preparation 
 Fresh bovine knee joints were obtained from Bichelmeyer Meats (Kansas City, 
MO) following sacrifice. Articular cartilage was excised, washed with phosphate 
buffered saline, processed into fragments using liquid nitrogen cryofracturing, and 
cryopreserved for storage until use. Cryopreservation was achieved by freezing the 
tissue in a cryoprotectant (RPMI with 10% FBS and 10% DMSO) at 1°C per minute 
using a controlled rate freezer (2100 Series, CustomBioGenics Systems, Romeo, MI) and 
stored at -180°C.  
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Previously cryopreserved cartilage fragments were thawed, packaged into 
dialysis tubing, and subjected to a reciprocating osmotic shock and multi-detergent 
and enzymatic washout protocol to remove cellular material as described 
previously.185 Briefly, cartilage fragments were first treated in hypertonic salt solution 
(HSS) for two hours at 21°C under gentle shaking, followed by treatment with the non-
ionic detergent Triton X 100 (TX100; 0.05% v/v; Sigma-Aldrich) in hypotonic, 
deionized, sterilized water for three hours. The tissue was rinsed with deionized water 
for ten minutes and subjected to a second round of treatment with HSS and TX100. 
The cartilage fragments were then treated in a Benzonase® solution (0.0625 KU ml-1; 
Sigma-Aldrich) overnight at 37°C under constant shaking (220 rpm) to digest nuclear 
material. Following Benzonase® treatment, cartilage fragments were rinsed in 
deionized water and further treated with the anionic detergent sodium-lauroyl 
sarcosine (NaLS; 1.0% v/v; Sigma-Aldrich) for 24 hours at 21°C under constant shaking 
(220 rpm). At the conclusion of the NaLS treatment, cartilage fragments were rinsed 
and treated with ethanol (40% v/v, Sigma-Aldrich) under gentle agitation. Extraction 
of organic solvents was then performed using ion exchange resins (Amberlite, Sigma-
Aldrich; Mixed Bead Resin TMD-8, Sigma-Aldrich; Dowex Monosphere, Supleco). The 
total duration of the decellularization process was 72 hours. Following 
decellularization, DCC was cryopreserved using the methods described previously and 
returned to cryostorage for later testing or processing. 
 In preparation for grinding, cryopreserved DCC fragments were thawed and 
subjected to five rinse cycles with deionized water to remove cryopreservation 
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medium. Tissue fragments were then lyophilized for 24 hours and then ground into a 
fine powder using a SPEX Freezer/Mill 6770 (SPEX Sample Prep, Metuchen, NJ) that 
was specifically designed for cryogenic grinding and pulverizing of tough and/or 
temperature sensitive samples, while immersed in liquid nitrogen. Conditions 
(impactor rate, grinding length, number of grinding cycles) were selected by 
preliminary studies to obtain a homogenous powder without burning the tissue by 
overgrinding. The resulting fine powder was removed and kept in the freezer at -20°C 
until further characterization or use. Prior to use for cell studies, DCC powder was 
sterilized by an Anprolene ethylene oxide sterilizer, using a 12-hour cycle (Andersen 
Products, Haw River, NC).  
 
3.3.2 Biochemical analysis 
 Double stranded DNA (dsDNA) was quantified fluorimeterically using the 
Quanti-iT High Sensitivity dsDNA Assay Kit (Molecular Probes Inc., Eugene, OR) as 
described previously.185 Briefly, fresh, cryopreserved, and decellularized tissue was 
digested using a ratio of 25 milligrams of tissue to 20 microliters of proteinase K. 
Complete digestion occurred after heating the tissue and solution at 56°C in a water 
bath overnight, with periodic vortexing. Total DNA purification was performed using 
the DNeasy Blood and Tissue Kit (DNeasy, Qiagen Inc., Valencia, CA) spin-column 
technique in accordance with the manufacturer’s recommended protocol. Purified 
samples were treated with the Quanti-iT dsDNA Assay Kit according to the protocol 
recommended by the manufacturer to selectively bind dsDNA with a fluorescent dye. 
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Native and cryopreserved samples were prepared for the assay by making a diluted 
supernatant of 10 μl of sample with 190 μl of supplied buffer. Decellularized samples 
were not diluted. Solutions were analyzed in triplicate using a fluorescence microplate 
reader (ThermoFisher) at 486/528 nm excitation/emission wavelengths. This dsDNA 
analysis was performed for bovine cartilage tissue in fresh, cryopreserved, and 
decellularized states (n = 5). DNA content is reported as micrograms of DNA per 
milligram of hydrated tissue. 
Sulfated GAG content was quantified colorimetrically using a commercially 
available sulfated GAG assay (Blyscan Sulfated Glycosaminoglycan Assay, Biocolor Ltd., 
UK). First, 50 milligrams of hydrated cartilage tissue was digested by adding 1.5 mL of 
papain solution comprising of 125 μg/mL papain (from papaya latex, Sigma), 5 mM N-
acetyl cysteine, 5 mM ethylenediaminetetraacetic acid (EDTA), and 100 mM potassium 
phosphate buffer in ddH2O (20mM monobasic potassium phosphate, 79 mM dibasic 
potassium phosphate in ddH2O). The cartilage tissue was placed in microcentrifuge 
tubes containing papain digestion solution and left overnight at 60°C and then placed 
in the freezer at -20°C until future biochemical analysis. GAG content was then 
measured using a dimethylmethylene blue (DMMB) sulfated GAG assay as 
recommended by the vendor and was performed on fresh, cryopreserved, and 
decellularized cartilage specimens (n = 5). GAG content is reported in micrograms of 
GAG per milligram of hydrated tissue. 
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3.3.3 Transmission electron microscopy (TEM) 
DCC dry powder samples (lyophilized for 24 hours prior) were prepared by 
suspending the cartilage powder in ethanol and agitating in an ultrasonic bath for 15 
minutes. 10 mL of DCC sample in ethanol was placed onto copper mesh grid with 
lacey carbon film. The wet grids were allowed to air-dry for several minutes prior to 
being examined under TEM. The particle size and morphology were examined by 
bright-field and dark-TEM using an FEI Technai G2 transmission electron microscope at 
an electron acceleration voltage of 200 kV. High resolution images were captured 
using a standardized, normative electron dose and a constant defocus value from the 
carbon-coated surfaces.  
 
3.3.4 Fourier transform infrared spectroscopy (FTIR)  
 Native and decellularized bovine cartilage were ground into fine powders as 
described previously. Separately, each of the powders was mixed with potassium 
bromide (KBr) and pressed into very thin tablets. Infrared spectra of each were 
obtained by using Perkin-Elmer Spectrum 400 Fourier transform infrared 
spectrophotometer (Perkin-Elmer, Waltham, MA) in transmission mode. 
 
3.3.5 Swelling 
 Decellularized cartilage was dried for 24 hours by lyophilization following 
grinding as described previously. Dry DCC powder was weighed and placed into 2 mL 
microcentrifuge tubes and an initial volume measurement was taken. 1 mL of 
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phosphate buffered saline (PBS) was added to each tube and the powder was given 24 
hours to swell. The volume and mass of the cartilage powder was then recorded and 
used to calculate an S-ratio and a V-ratio. The S-ratio was defined as the mass of the 
swelled tissue minus the mass of the dry tissue, divided by the mass of the dry tissue 
((Mswell - Mdry)/Mdry). The V-ratio was defined as the volume of the swelled tissue minus 
the volume of the dry tissue, divided by the volume of the dry tissue ((Vswell – Vdry)/Vdry). 
Three trials were performed to quantify the swelling of the DCC dry powder. 
 
3.3.6 Cell harvest, expansion, pellet culture, and encapsulation 
 Rat bone marrow stem cells (rBMSCs) were obtained from the femurs of male 
Sprague-Dawley rats (150-200 g, Charles River Laboratories) following a University of 
Kansas approved IACUC protocol (#175-08). Briefly, all rats were euthanized by 
exposure to CO2 for five minutes with a death confirmation thoracotomy followed by 
removal of the leg bones. The femur was then separated from the tibia under sterile 
conditions and all excess muscle was removed. The marrow cavity was then flushed 
out of the femur using a syringe filled with 1% Antibiotic-Antifungal/PBS solution. All 
cells obtained were plated for expansion in monolayer and incubated at 37°C. The 
culture medium for rBMSCs was composed of Alpha MEM, 1% Penicillin-Streptomycin, 
10% qualified fetal bovine serum (Invitrogen Life Technologies, Carlsbad, CA) and was 
changed every two days. At 80-90% confluence, cells were passaged and plated at 
40,000 cells/cm2. Cells were expanded to passage 4 (P4) to be used for pellet culture 
and encapsulation studies.  
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 For formation into pellets, P4 cells were counted and placed into 15 mL 
centrifuge tubes at a density of 2 million cells/tube and centrifuged to create a cell 
pellet in the bottom of the tube for culture. Control samples were defined as an rBMSC 
pellet with no added DCC powder (-DCC), while the other experimental group was two 
million cells pelleted with 5 milligrams of DCC powder (+DCC). Each 15 mL tube was 
placed inside a 75 cm2 flask to maintain air flow and sterile culture conditions in the 
incubator at 37°C. One mL of standard chondrogenic medium was placed in each 
tube. Medium consisted of high glucose DMEM, 1% Penicillin-Streptomyocin, 1X 
Insulin-Transferrin-Selenium (ITS)-premix, 100 μM sodium pyruvate, 1% non-essential 
amino acids (all listed previous from Invitrogen Life Technologies, Carlsbad, CA), 40 
μg/mL L-proline (Sigma), 50 μg/mL L-ascorbic acid (Sigma), 100 μM dexamethasone 
(Sigma). Cell culture medium was changed on days three and six of the seven-day 
culture period. 
 Cell encapsulation in agarose hydrogels was performed as described in 
previous studies with slight modifications.186, 187 First, a 3% w/v solution of agarose in 
PBS was prepared and autoclaved for 30 minutes.  Meanwhile, rBMSCs were 
trypsinized to P4 and counted.  After removal from autoclave and cooling in a sterile 
environment to 39°C, the cell suspension was added to the agarose solution in a 1:2 
ratio to produce a 2% agarose solution with a seeding density of 10 million cells/mL.  
For the control group, no DCC powder was added to the agarose solution. For 
additional experimental groups, 10 mg DCC/mL agarose solution, 50 mg DCC/mL 
agarose solution, and 100 mg/mL agarose solution were added to make a total of four 
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experimental groups. For each group, agarose solution was pipetted into sterilized 
silicone rubber molds (~5mm diameter, ~2mm height, volume = 0.04 mL per gel), 
pressed between two glass slides, and cooled at 4°C for 10 minutes. The cell-
encapsulated gels were then added to untreated 24-well plates (Becton Dickenson; 
Franklin Lakes, NJ), supplied with 2 mL standard chondrogenic medium (as described 
previously), and placed in a sterile 37°C incubator. Medium was changed every 48 
hours for the 3-week duration of the study. 
 
3.3.7 Quantitative polymerase chain reaction  
In preparation for RT-PCR, pellet samples (n = 3) at day 1 and day 7 were first 
preserved in RNALater solution (Qiagen, Valencia, CA) and the RNA was isolated 
according to the manufacturer’s guidelines using a RNeasy kit (Qiagen). Isolated RNA 
was converted to cDNA using a TaqMan High Capacity kit (Applied Biosystems, Foster 
City, CA) in an Eppendorf Realplex ThermoCycler. TaqMan Gene expression assays 
from Applied Biosystems for rat collagen type I (COL1A1, Rn01463848_m1), collagen 
type II (COL2A1, Rn01637087_m1), SRY-box 9 (Sox9, H Rn01751069_mH), aggrecan 
(Acan, Rn00573424_m1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 
Rn01775763_g1) were used in conjunction with an Eppendorf Realplex Real-time PCR 
System (Eppendorf, Happuage, NY). The 2−ΔΔCt method was used to quantify the 
relative level of expression for each gene as reported previously.188 For quantification, 
one control sample without DCC (-DCC) at day 1 was designated as a calibrator, and 
GAPDH expression was used as an endogenous control. 
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3.3.8 Picogreen assay 
 Cell-encapsulated hydrogels from each group (n = 3) were harvested at week 0 
(24 hours after encapsulation), week 1, and week 3. Hydrogels were homogenized and 
digested in a papain solution as described previously. DNA content was quantified 
using a Picogreen assay (Molecular Probes, Eugene, OR) according to the 
manufacturer’s instructions. Based on previous studies, a conversion factor of 8.5 pg 
DNA/cell was used to calculate cell number for bone marrow stem cells.189  
 
3.3.9 Statistical analyses 
Statistical analyses were performed using a single factor analysis of variance 
(ANOVA) in IBM SPSS 22.0 software (SPSS, Inc., Chicago, IL), followed by a Tukey’s 
Honestly Significant Difference post hoc test when significance was detected below 
the p = 0.05 value. All quantitative results (numerical values and figures) were 
expressed as the average ± standard deviation. 
 
3.4 RESULTS 
3.4.1 DNA content 
 DNA content (Fig. 2) was significantly reduced (p < 0.005) between fresh and 
decelled tissue (n = 5).   The overall reduction of dsDNA content from fresh to 
decellularized was 98.9%.!!
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3.4.2 GAG content  
 GAG content (Fig. 3) slightly decreased in each stage of tissue 
processing (n=5) from fresh to cryopreserved to decellularized states. There was a 
significant reduction in GAG content from fresh to decellularized tissue (p < 0.01), 
although over 87% of native GAGs remained. 
 
 
 
Figure 2. Double-stranded DNA (dsDNA) content in native, cryopreserved, and 
decellularized bovine cartilage tissue calculated as micrograms (μg) of dsDNA 
per milligram (mg) of hydrated tissue. All values are expressed as the average ± 
standard deviation (n = 5), p < 0.05, * = statistically signicant dierence from 
the control (fresh). 
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3.4.3 Particle size 
 TEM revealed a fine and relatively monodisperse dry DCC powder with particle 
diameter ranging from 20-30 nm in size (Fig. 4 - A). Under higher magnification, DCC 
particles appear to have a hexagonal shape with slightly rounded edges (Fig. 4 – B). 
* 
Figure 3. Glycosaminoglycan (GAG) content in native, cryopreserved, and 
decellularized bovine cartilage tissue calculated as micrograms (μg) of GAG 
per milligram (mg) of hydrated tissue. All values are expressed as the average 
± standard deviation (n = 5), p < 0.05, * = statistically signicant dierence 
from the control (fresh). 
 
0 
0.5 
1 
1.5 
2 
2.5 
Fresh Cryopreserved Decelled 
G
A
G
 c
on
te
nt
 (μ
g/
m
g 
hy
dr
at
ed
 ti
ss
ue
) 
!
 
),!
Figure 4. TEM images of DCC powder. White arrows distinguish DCC particles on a lacy carbon 
lm. (A) shows a view of several particles of relatively equal diameters in the 20-30 nm range 
and (B) shows a zoomed in view of a single particle that is approximately 25 nm in diameter.  
 
3.4.4 Chemical composition 
 FTIR spectra of native and DCC specimens (Fig. 5) showed nearly identical 
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Figure 5. FTIR spectra of native and decellularized bovine cartilage. Both spectra appear to be 
relatively similar with only minor discrepancies. 
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signature peaks. Areas where the two samples may differ are noticed at 1405 cm-1 and 
1029 cm-1 where peaks are missing from the DCC spectrum that are apparent in the 
native cartilage spectrum. Chemical composition appears relatively unchanged. 
 
 
3.4.5 Swelling 
 From the swelling results of three trials with DCC dry powder, it is evident that 
the powder swells approximately 475% (Table 7). Therefore, in a hydrated state, it is 
reasonable to calculate that DCC particles would swell from 25-30 nm to 
approximately 150 nm.  
Trial Swell Density (mg/mL) S-Ratio ((Mswell-Mdry)/Mdry)) V-Ratio ((Vswell-Vdry)/Vdry))
1 81.5 1178% 440%
2 79.5 1190% 478%
3 77.0 1253% 500%
Mean 79.3 1207% 473%
SD 2.2 40% 30%
Table 7. Swelling data for DCC dry powder. 
 
 
3.4.6 Gene expression 
 Both the control (-DCC powder) and +DCC pellet groups expressed a small 
level of collagen type II at day 1 (Fig. 6). At day 7, however, collagen II expression 
increased significantly in both groups from day 1 and the +DCC pellet group 
expressed nearly two-fold significantly greater collagen II expression when compared 
to the control group (p < 0.002). 
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Figure 6. Relative gene expression of collagen type II (COL2A1) for pellet culture 
samples with (+DCC) and without DCC (-DCC) powder. All values are expressed 
as the average ± standard deviation (n = 3), p < 0.05, # = statistically signicant 
dierence from Day 1 value, * = statistically signicant dierence from the other 
group at that time point.  
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Sox9 expression (Fig. 7) was significantly greater in the control group (-DCC) 
when compared to the +DCC group at day 1 (p < 0.014). At day 7, Sox9 expression in 
the control group significantly decreased by over 66% in comparison to the day one 
value (p < 0.008). Sox9 expression was over three-fold greater in the DCC group when 
compared to the control at day 7, but this increased expression was not significant (p 
= 0.256). 
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Figure 7. Relative gene expression of Sox9 for pellet culture samples with 
(+DCC) and without DCC (-DCC) powder. All values are expressed as the average 
± standard deviation (n = 3), p < 0.05, @ = statistically signicant dierence from 
Day 1 value, * = statistically signicant dierence from the other group at that 
time point.  
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No significant differences were observed in collagen type I expression between 
groups or time points (Fig. 8). On day 1, the +DCC group seemed to have less collagen 
type I expression than the control (p = 0.14). Furthermore, collagen type I expression 
on day 7 in +DCC samples when compared to –DCC samples appeared slightly less as 
well (p  = 0.937). Sizeable standard deviations in each group, however, did not allow 
for discernable differences between groups. 
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 Like collagen type I, aggrecan expression (Acan) was not significant in either 
group or time point (Fig. 9). Aggrecan expression appeared be slightly greater in the 
+DCC group at both time points, however, the sizeable standard deviation each of 
these make it difficult to conclude with any certainty. The p-values comparing 
aggrecan expression of +DCC and –DCC groups were p = 0.302 and p = 0.773, for day 1 
and day 7 respectively. 
 
Figure 8. Relative gene expression of collagen type I (COL1A1) for pellet culture 
samples with (+DCC) and without DCC (-DCC) powder. All values are expressed 
as the average ± standard deviation (n = 3). There were no statistically signicant 
dierences in the expression of collagen type I between control BMSCs and 
BMSCs with DCC powder. 
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Figure 9. Relative gene expression of aggrecan (Acan) for pellet culture samples 
with (+DCC) and without DCC (-DCC) powder. All values are expressed as the 
average ± standard deviation (n = 3). There were no statistically signicant 
dierences in the expression of Acan between control BMSCs and BMSCs with 
DCC powder. 
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3.4.7 DNA content of cell-encapsulated hydrogels 
 At week 0 (24 hours following cell encapsulation), all groups had no significant 
differences in DNA content (Fig. 10). At week 1, all groups decreased in DNA content 
from week 0 but these changes were not significant. At week 3, the blank group (no 
DCC powder) significantly decreased in comparison to its week 0 value (p < 0.025). 
From week 1 to week 3, the 10 mg/mL DCC and 100 mg/mL DCC groups rebounded to 
near initial (week 0) values. The 50 mg/mL DCC group appeared to have degraded 
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more quickly then other groups and fell apart by week 3, which led to this group 
having the lowest DNA content at this timepoint. 
Figure 10. DNA content for groups at 0, 1, and 3 weeks. Values are reported as mean ± 
standard deviation (n = 3), !! "! #$#%&! '! (! )*+,),-+../! )01203-+2*! -4+215! 6789!:55;! #!
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3.5 DISCUSSION 
 The primary objective of this study was to evaluate the potential of DCC as a 
raw material scaffold component for cartilage tissue engineering applications and to 
initially test its ability to induce chondrogenesis in bone marrow stem cells. To the 
best of our knowledge, this was the first effort to characterize stem cell response to 
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DCC through quantification of gene expression of chondrogenic markers (COL2A1, 
Sox9, Acan).  
 First, bovine articular cartilage was decellularized in tissue fragments and 
characterized for DNA content and GAG content in fresh, cryopreserved, and 
decellularized states. DNA content was reduced by 98.9% from fresh to decellularized 
states, while preserving over 87% of native GAG content. To the best of our 
knowledge, this is the greatest ratio of DNA reduction – GAG retention achieved by 
any decellularized cartilage study in the literature to date. The use of a highly-
developed decellularization protocol utilizing advanced surfactants may be one 
reason for this high ratio. Additionally, tissue cryopreservation as close to euthanasia 
of the animal as possible may also contribute to the overall decellularization outcome. 
 A challenge in this study was finding a method for processing DCC fragments 
into a fine and more homogenous powder post-decellularization. The tough and 
gummy nature of cartilage tissue made it extremely difficult to find an apparatus for 
this procedure. After attempting several grinding options that ranged from 
homogenizers to dry ice grinders, the selection of a liquid nitrogen based mill and 
optimization of parameters for the SPEX Freezer/Mill produced a fine and 
homogenous powder that was confirmed to have a dry particle size in the range of 20-
30 nm by TEM. Production of an ECM-based nanopowder is extremely rare in the 
literature; to the best of our knowledge, ECM-based nanopowder has never been 
reported with hyaline cartilage. The smallest particles of decellularized cartilage 
reported in the literature have been 2 μm “cartilage dust” by Ghanavi and 
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colleagues.182 
 Another factor that must be considered when examining particle size is 
swelling. Nearly all DCC studies in the literature have overlooked this parameter; 
however, the nature of cartilage tissue and its constituent highly negatively charged 
proteoglycans make DCC susceptible to sizeable swelling. In our experimental 
observations, DCC dry powder tends to swell about 4.75 times in volume in biological 
medium. This would translate to the DCC hydrated nanopowder being approximately 
100 - 150 nm. Using similar logic, other DCC studies, such as the “cartilage dust” 
mentioned previously, would have demonstrated results with a hydrated particle size 
of about 10 μm. While it is not well understood which particle size may be more 
advantageous for cartilage tissue engineering scaffolds, it seems apparent that the 
nanopowder would be able to be incorporated into many different scaffold 
formulations – hydrogels, microparticles, colloidal systems – more readily than a 
micropowder.  
 One concern about this degree of tissue decellularization and tissue processing 
was the potential for chemical composition changes to occur. Transmission FTIR, 
however, confirmed only slight differences in the spectra of native and DCC tissue 
samples. The missing peaks in the DCC spectrum at 1405 cm-1 and 1029 cm-1 could 
represent crystallization in the tissue due to freeze-thaw cycles that are apparent in 
the steps from fresh cartilage tissue harvest to DCC nanopowder. It is not apparent 
that these wavelengths correspond directly to any well-known functional groups; 
however, higher resolution techniques may be helpful in making a more defined 
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determination.  
 Response of rBMSCs, quantified by gene expression, was a main focus of this 
study following the material development and characterization of DCC powder. While 
prior work in the literature has concentrated on maintenance of the phenotype of 
chondrocytes, this work centered on the ability of DCC to induce chondrogenesis by 
selecting chondrogenic markers (collagen type II, Sox9, and aggrecan) to quantify 
their expression in rBMSCs cultured in standard chondrogenic medium with and 
without DCC powder. It is important to note that no growth factors were added to this 
medium. Overall, the rBMSCs cultured with DCC powder appeared to have greater 
chondrogenic expression of collagen II and Sox9 markers by two-fold and three-fold, 
respectively. The gene expression results of aggrecan, the main proteoglycan in 
hyaline cartilage, appeared statistically inconclusive. Likewise, collagen type I 
expression would be expected to be downregulated during chondrogenesis due to its 
minute presence in hyaline cartilage tissue; however, those results were also 
statistically inconclusive. Larger sample sizes would be needed and should be a main 
goal for future work to determine the chondoinductivity of DCC. 
 Lastly, the study examined cell proliferation in response to DCC powder with 
rBMSCs encapsulated in an agarose hydrogel. Agarose was hypothesized to be a 
potential delivery vehicle for DCC in a three-dimensional scaffold. It was evident that 
gels containing 10 mg DCC/mL and 100 mg DCC/ mL retained DNA content over the 
3-week culture period, while DNA content of blank hydrogels decreased significantly 
over the same period.  The hydrogels containing 50mg DCC/mL appeared to degrade 
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substantially over the 3-week culture period suggesting that loading concentration 
may need to be examined more intensively in future work. While agarose was selected 
for its inert nature, it appears that rBMSCs may not fare as well encapsulated in this 
material as chondrocytes. Previous studies have shown that chondrocytes proliferate 
in agarose;187, 190, 191 however, this study suggests that a different delivery method may 
be more suitable for rBMSC proliferation. Fibrin glue has been well studied and is used 
to deliver chondrocytes to chondral defects in the ACI procedure clinically.192 Future 
studies with DCC should attempt to examine fibrin glue for the delivery of DCC in a 
thee-dimensional scaffold. 
 Lastly, we acknowledge that this work was not without limitation. Hyaline 
cartilage tissue properties and composition can vary greatly from batch to batch 
based on: 
• Harvest time after euthanasia 
• Age of the animal 
• Species/breed 
• Activity level of the animal 
Therefore, the results obtained in this study regarding DNA content and GAG content 
could also vary. Repeatability should be addressed in future studies. Additionally, the 
assay used for GAG content examines only sulfated GAG content, which leaves out the 
only non-sulfated GAG, hyaluronic acid (HA). It is not well understood if HA is also 
preserved in the decellularization process. Sample sizes in this study for cellular 
response and proliferation were limited due to availability of tissue powder. Future 
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studies will need to occur with greater samples sizes. Finally, we acknowledge that the 
immunological response of cells to the DCC nanopowder was not characterized in this 
study. While skepticism about the biocompatibility of having not only an ECM-based 
material but also a nanomaterial may occur, future studies should examine this both in 
vitro and in animal models. 
 Overall, this study lays a foundation for future work developing and 
characterizing DCC as a chondroinductive material for cartilage tissue engineering. 
Preliminary gene expression results seem promising as well as the ability of our 
method to have an unmatched DNA reduction: GAG preservation ratio. In the search 
to find raw materials that provide both a biological scaffold and microenvironmental 
cues, DCC may help provide a solution to mitigate the growing problem associated 
with cartilage defects that exists throughout the world.  
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CHAPTER 4: Conclusion 
 Previous studies have attempted to decellularize hyaline cartilage and have 
examined the ability of this raw material to maintain phenotype of chondrocytes with 
success. The studies in this thesis made the first attempt to characterize stem cell gene 
expression in response to DCC powder. Our results examined the potential of DCC to 
induce chondrogenesis in bone marrow stem cells. 
Bovine articular cartilage was harvested, cryopreserved, and decellularized. The 
tissue was evaluated for DNA and sulfated GAG content at fresh, cryopreserved, and 
decellularized states. The findings showed that this study was the first to demonstrate 
a high percentage of cell removal along with a high percentage of GAG retention. 
Additionally, this study was the first to process DCC into a nanomaterial for 
incorporation of this raw material into a wide variety of scaffold formulations. The 
chondroinductivity of DCC was tested in pellet culture with rBMSCs with and without 
DCC powder. Gene expression results yielded a two-fold upregulation of collagen type 
II and three-fold upregulation of Sox9 in pellets cultured with DCC. Aggrecan and 
collagen type I expression proved inconclusive. This may be attributed to a limited 
sample size or may suggest a partial differentiation of stem cells down a chondrogenic 
lineage. 
Future work can address the limited sample sizes that were used for gene 
expression and cell proliferation in this study and examine repeatability.  Use of a 
different delivery scaffold, such as fibrin glue, may be an advantageous choice for this 
project due to the use of fibrin glue in treating chondral defects clinically. Determining 
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non-sulfated GAG content in pre- and post-decellularized tissue should also be 
explored. Immunological response in vitro and in animal models would seem to be a 
high priority in order to take this work further. Determining proteoglycan 
concentration pre- and post-decellularization would be important to know and may 
be able to be quantified using ELISA assays. Finally, a comparison study between the 
ability of the DCC nanopowder developed in this study to retain phenotype of 
chondrocytes versus induce chondrogenesis of stem cells would seem to be of utmost 
importance to the field of cartilage tissue engineering. Currently, autologous 
chondrocytes are used clinically in the ACI procedure for treating cartilage defects; 
however, the potential ability of DCC to induce chondrogenesis of stem cells while 
also providing native cartilage building blocks may provide an alternative clinically in 
the future. 
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